New Swedish technology to cure chronic wounds
With genetically rebuilt lactic acid bacteria Evelina Vågesjö, new doctor at Uppsala University and president of Ilya Pharma, is well on her way to solve one of healthcares greatest challenges.
- Chronic wounds are a very common problem that causes extreme agony for the victims and requires great healthcare resources. With our new biotherapeutics, we hope to accelerate the healing process with up to 80 percent, while the use of antibiotics can be reduced during treatment!
Less than five years have passed since Evelina Vågesjö, then newly doctoral student at Uppsala University, began considering the possibilities of modifying lactic acid bacteria to deliver biologics to the wound. Today the doctor's hat is on the shelf with Evelina taking the project further as CEO of the newly formed company Ilya Pharma. Her redesigned bacteria exhibit unique effects in experiments on mice, and during 2017 the first clinical tests awaits.
- For the next phase, we need to bring in about three million Euro, but we are receiving excellent support from Uppsala Innovation Centre and UU Innovation, and our results arouses great interest in both the pharmaceutical industry and from venture capital companies, so it appears we will manage funding, says Evelina Vågesjö laboratory Uppsala Biomedical Center.
The new technology attracts attention far beyond the borders of Sweden. EIT Health – the European consortium that has EU’s mission to take on the healthcare challenges facing society – chose early on to support the development of Ilya Pharma, and when Evelina Vågesjö presented the results of their work at the EIT Health's annual meeting in Barcelona she was awarded - in hard competition from other young researchers - continued funding to take her innovation further.
- Receiving the support of EIT Health gives us both a qualitymark that will hopefully facilitate our future operations, as well as access to a wider European network. During 2017 we are invited to present Ilya Pharma at the Global Investor Forum in Maastricht, and we also hope to initiate new partnerships at the EIT Health Matchmaking Event in Uppsala which can strengthen our position in major European calls.
Still, much work remains before Evelina Vågesjös bacteria are ready to meet the market, but she and her colleagues at Ilya Pharma heads firmly forward. Their patents are in demand and if test responses remain positive the negotiating regarding license manufacturing and external ownership draws nearer.
- So far we have because of limited resources focused on ulcers in patients with diabetes, but our technology has the potential to be applied to all acute and chronic wounds, and as soon as we validate the concept, we can take the next big step on the amazing journey my former supervisor, Professor Mia Phillipson let me begin. Today we are five people and a number of consultants who collaborate in this project and Ilya Pharma, and wherever the road takes us it is a great inspiration to experience the powerful transmission that occurs when different skills come together and strive towards a common goal!
Study shows strong impact of EIT's work
2017-12-12A new study published in late November by the EIT reveals substantial impact from the work of EIT Health and the other Knowledge Innovation Communities (KICs) founded by the EIT. ...
3 million EUR to new method to treat chronic wounds
2017-12-11The EU Commission funds 3 million EUR to Evelina Vågesjö, researcher at Uppsala University and CEO of Ilya Pharma, for further development of a new technique to treat acute and chronic wounds. ...
Innovation Day attracts international interest
2017-12-07Just a moment ... Lina Sors Emilsson, project manager for the EIT Health Innovation Day that December 1 gathered students and representatives of Uppsala Municipality and Uppsala Region aiming to creat...
EIT Health 2019 Calls for proposals Alert
2017-12-05The EIT Health 2019 Calls for proposals are about to open for all partners. EIT Health will give webinars on financial and administrative topics to assist anyone planning to participate in the calls. ...
New PhD school CREOLE gets EIT Health support
2017-11-29EIT Health announces support to the upcoming PhD school Convergence Research Education Obtaining Leverage for Enterprise (CREOLE), a cross-disciplinary initiative in the works at Uppsala and Groningen...